Will Pizii

The phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.

No grade 3 TEAEs were reported in more than 1 patient at a time, and investigators deemed these grade 3 TEAEs to be unrelated to darolutamide treatment.

The final results from the phase 3 ARCHES trial showed that the addition of enzalutamide to androgen deprivation therapy also continued to improve radiologic progression-free survival and other secondary end points.

Naomi B. Haas, MD, discusses efforts to improve care in locally advanced renal cell carcinoma through research in the neoadjuvant setting.